Signet, Bionpharma and GMS Form Pharma Nobis to Acquire Fagron's U.S. Contract Manufacturing Business

LGM Pharma Acquires Nexgen Pharma's Drug Product CDMO Business

July 23, 2020

Pharmaceuticals

LGM Pharma has acquired the formulation development and drug product contract manufacturing business of Nexgen Pharma, expanding LGM's CDMO capabilities and U.S.-based manufacturing footprint. Financial support for the transaction was provided by private equity firm New Harbor Capital; Nexgen Pharma sold its pharmaceutical CDMO unit to allow the company to focus on other healthcare segments.

Bora Pharmaceuticals Acquires Upsher-Smith Laboratories

August 5, 2025

Pharmaceuticals

Bora Pharmaceuticals completed a 2024 acquisition of Upsher-Smith Laboratories for $210 million and is expanding the Maple Grove, Minnesota manufacturing site with a multi-year buildout. The investment includes installation of a Gerteis Macro-Pactor (operational Q3 2025) and development of 100,000 square feet of shell space to boost oral solid dose (OSD) contract development and manufacturing capabilities.

AmerisourceBergen Acquires PharmaLex from AUCTUS in €1.28bn Transaction

December 31, 2022

Healthcare Services

AmerisourceBergen Corporation acquired a majority stake in PharmaLex from funds advised by AUCTUS Capital Partners AG in a transaction that closed at year-end 2022 for approximately EUR 1.28 billion. PharmaLex, a Germany-headquartered provider of regulatory, clinical development and pharmacovigilance services to the life sciences industry, was grown under AUCTUS through a buy-and-build program of 38 add-ons and will expand AmerisourceBergen's global pharmaceutical solutions.

Signet Healthcare Partners Provides Growth Equity to Ascendia Pharmaceuticals

April 8, 2021

Pharmaceuticals

Signet Healthcare Partners, a New York-based growth equity firm, has made a growth equity investment in Ascendia Pharmaceuticals, a North Brunswick, New Jersey-based specialty CDMO. The proceeds will fund Ascendia's facility expansion and increased manufacturing capacity; Signet principals James Gale and Dr. Theron Odlaug will join Ascendia's board.

Fagron Acquires Purifarma in Brazil

January 6, 2026

Pharmaceuticals

Fagron has completed the acquisition of Purifarma, a large-scale pharmaceutical essentials business in Brazil, for an enterprise value of approximately R$250 million. The deal strengthens Fagron's scale and procurement position in Latin America and supports the Group's buy-and-build strategy to expand its pharmaceutical compounding and essentials platform.

ANI Pharmaceuticals Acquires Novitium Pharma for $163.5M

March 9, 2021

Pharmaceuticals

ANI Pharmaceuticals completed the acquisition of Novitium Pharma for $163.5 million (including $89.5M cash and $74M equity, plus up to $46.5M in contingent earn-outs), adding a U.S.-based R&D engine and CDMO manufacturing capacity. The deal, financed with a new $300M Term Loan B, a $40M revolver and a $25M PIPE investment from Ampersand Capital Partners, is expected to be immediately accretive and expand ANI's generics, contract manufacturing and 505(b)(2) capabilities.